Impel NeuroPharma Stock Forecast, Price & News

Impel NeuroPharma (NASDAQ:IMPL) Frequently Asked Questions

Is Impel NeuroPharma a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Impel NeuroPharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Impel NeuroPharma stock.
View analyst ratings for Impel NeuroPharma or view top-rated stocks.

What stocks does MarketBeat like better than Impel NeuroPharma?

Wall Street analysts have given Impel NeuroPharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Impel NeuroPharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Impel NeuroPharma?

Impel NeuroPharma saw a decline in short interest during the month of October. As of October 15th, there was short interest totaling 784,800 shares, a decline of 16.5% from the September 30th total of 940,100 shares. Based on an average daily volume of 704,700 shares, the days-to-cover ratio is presently 1.1 days. Approximately 12.0% of the company's stock are sold short.
View Impel NeuroPharma's Short Interest.

When is Impel NeuroPharma's next earnings date?

Impel NeuroPharma is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Impel NeuroPharma.

How were Impel NeuroPharma's earnings last quarter?

Impel NeuroPharma, Inc. (NASDAQ:IMPL) announced its quarterly earnings results on Monday, August, 16th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by $0.19.
View Impel NeuroPharma's earnings history.

What price target have analysts set for IMPL?

3 Wall Street analysts have issued twelve-month price objectives for Impel NeuroPharma's shares. Their forecasts range from $21.00 to $55.00. On average, they anticipate Impel NeuroPharma's share price to reach $36.00 in the next twelve months. This suggests a possible upside of 257.5% from the stock's current price.
View analysts' price targets for Impel NeuroPharma or view top-rated stocks among Wall Street analysts.

Who are Impel NeuroPharma's key executives?

Impel NeuroPharma's management team includes the following people:

• Mr. Adrian Adams, Chairman, CEO & Pres (Age 70) (LinkedIn Profile)
• Dr. John D. Hoekman Ph.D., Co-Founder, Chief Technology & Devel. Officer and Director (Age 40)
• Dr. John H. Leaman, Chief Financial Officer (Age 48)
• Ms. Jennifer L. Berman, VP of Marketing
• Ms. Patty Billingsley, VP of Sales
• Mr. Leonard S. Paolillo, Chief Commercial Officer (Age 42)
• Dr. Stephen Bevan Shrewsbury, Chief Medical Officer (Age 64)
• Dr. Lynn C. Gold, Sr. VP of Regulatory Affairs (Age 64)
• Mr. Scott Youmans, Sr. VP of Technical Operations (Age 54)

Who are some of Impel NeuroPharma's key competitors?

Some companies that are related to Impel NeuroPharma include VBI Vaccines (VBIV), Phathom Pharmaceuticals (PHAT), Akero Therapeutics (AKRO), Oramed Pharmaceuticals (ORMP), Lexicon Pharmaceuticals (LXRX), Kiniksa Pharmaceuticals (KNSA), Collegium Pharmaceutical (COLL), Dyne Therapeutics (DYN), POINT Biopharma Global (PNT), Gracell Biotechnologies (GRCL), Immuneering (IMRX), Amryt Pharma (AMYT), Emisphere Technologies (EMIS), OrganiGram (OGI) and Eagle Pharmaceuticals (EGRX).
View all of IMPL's competitors.

When did Impel NeuroPharma IPO?

(IMPL) raised $80 million in an initial public offering on Friday, April 23rd 2021. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow served as the underwriters for the IPO.

What is Impel NeuroPharma's stock symbol?

Impel NeuroPharma trades on the NASDAQ under the ticker symbol "IMPL."

When did Impel NeuroPharma's lock-up period expire?

Impel NeuroPharma's lock-up period expired on Wednesday, October 20th. Impel NeuroPharma had issued 5,333,334 shares in its IPO on April 23rd. The total size of the offering was $80,000,010 based on an initial share price of $15.00. Since the expiration of Impel NeuroPharma's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Who are Impel NeuroPharma's major shareholders?

Impel NeuroPharma's stock is owned by a number of retail and institutional investors. Top institutional investors include FNY Investment Advisers LLC (0.03%). Company insiders that own Impel NeuroPharma stock include Adrian Adams, Global Strategic Fund I Venbio and Vivo Capital Viii, Llc.
View institutional ownership trends for Impel NeuroPharma.

Which major investors are buying Impel NeuroPharma stock?

IMPL stock was acquired by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Impel NeuroPharma stock in the last two years include Adrian Adams, and Vivo Capital Viii, Llc.
View insider buying and selling activity for Impel NeuroPharma or or view top insider-buying stocks.

How do I buy shares of Impel NeuroPharma?

Shares of IMPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Impel NeuroPharma's stock price today?

One share of IMPL stock can currently be purchased for approximately $10.07.

How much money does Impel NeuroPharma make?

Impel NeuroPharma has a market capitalization of $196.47 million.

How many employees does Impel NeuroPharma have?

Impel NeuroPharma employs 59 workers across the globe.

What is Impel NeuroPharma's official website?

The official website for Impel NeuroPharma is www.Impelnp.com.

How can I contact Impel NeuroPharma?

The company can be reached via phone at 206-568-1466.